Live
- Jaya Bachchan Begins Filming for ‘Dil Ka Darwaaza Khol Na Darling’ with Siddhant Chaturvedi and Wamiqa Gabbi
- Telangana Issues Legal Notice to Diljit Dosanjh Ahead His Concert in Hyderabad
- Suriya's Kanguva Opens Strong at Box Office, Despite Mixed Reviews and Piracy Threats
- Delhi's Air Quality Hits "Severe" Levels: Key Updates
- Top diplomats of South Korea, Japan hold talks on sidelines of APEC summit in Peru
- CATL Chairman Doubts Elon Musk's 4680 Battery Will Succeed
- PM Modi Pays Tribute to Birsa Munda on His Birth Anniversary, Marks Janjatiya Gaurav Divas with Special Visit
- Actor Suriya’s ‘Kanguva’ Leaks Online Hours After Theatrical Release
- Chandrababu's Andhra Pradesh Investment & Job Creation Plans (BN) for Industrial Growth
- Shankar’s daughter Aditi Shankar set to debut in Tollywood
Suven Life gets 7 product patents
Biopharmaceutical firm Suven Life Sciences on Wednesday said it received one product each from Europe, Hong Kong, Japan, Macau, the African Regional Intellectual Property Organisation (ARIPO) and South Korea for a drug used in the treatment of neuro-degenerative diseases.
Hyderabad: Biopharmaceutical firm Suven Life Sciences on Wednesday said it received one product each from Europe, Hong Kong, Japan, Macau, the African Regional Intellectual Property Organisation (ARIPO) and South Korea for a drug used in the treatment of neuro-degenerative diseases.
The patents, which are valid till 2031, are to their New Chemical Entities (NCEs) for CNS therapy.
"We are very pleased by the grant of these patents to Suven for our pipeline of molecules in the CNS arena, which are being developed for cognitive disorders with high unmet medical need with a huge market potential globally," said Venkat Jasti, CEO, Suven Life Sciences.
With these new patents, Suven has a total of 1 granted patent from ARIPO (African Regional Intellectual Property Organisation), 19 from Europe, 18 from Hong Kong, 18 from Japan, 7 from Macau and 18 from South Korea.
These granted patents are exclusive intellectual property of Suven and are achieved through internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like phase-I or phase-II, the company said.
